Results 121 to 130 of about 4,142 (167)

Comparative effectiveness of IL-12/23 and IL-23 inhibitors versus JAK inhibitors in patients with inflammatory bowel disease and hidradenitis suppurativa: a real-world propensity-matched analysis. [PDF]

Crohns Colitis 360
Hafez Y, Osman A, Syn WK, Shmais M.
europepmc   +1 more source

Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease. [PDF]

J Gastroenterol Hepatol
Ooi CJ, Ling KL, Limsrivilai J, Wei SC, Mak JWY, Kobayashi T, Dang LM, Leong RW, Lin H, Weng MT, Ong WC, Ahuja V, Aniwan S, Hokari R, Lee WJJ, Leow AH, Leung WK, Lim WC, Makharia G, Matsuoka K, Mustaffa N, Ng SC, Philip M, Pisespongsa P, Ali RAR, Ran ZH, Simadibrata M, Sollano J, Tan M, Viet HD, Wan Ibrahim NR, Wu KC, Ye BD, Hilmi I, Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease Committee and Asian Education Network in IBD (AEN‐IBD).   +34 more
europepmc   +1 more source

Factors Associated With PASI90 Maintenance Without Flare-Up and Predictors of Biologics Discontinuation in Psoriasis: Two-Center Retrospective Cohort Study in Korea. [PDF]

Ann Dermatol
Choi MS, Yeom K, Jung SW, Hong SP, Kong KA, Kim MH.   +5 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan. [PDF]

Dermatol Ther (Heidelb)
Igarashi A, Shiraishi K, Saito S, Kudo T, Iizuka Y, Yamamura E, Hase M.   +6 more
europepmc   +1 more source

Case Report: Upadacitinib and apremilast combination therapy for guselkumab-induced paradoxical eczema in psoriasis. [PDF]

Front Immunol
Yang L, Zhou J, Ruan Z, Shi K.
europepmc   +1 more source

First-Line Guselkumab Combined with Exclusive Enteral Nutrition in Biologic-Naïve Young‑Onset Crohn's Disease: A Three-Case Series from China. [PDF]

J Inflamm Res
Sha S, Xu B, Qiao C, Wang K, Liu L, Wu J, Ma W, Shi A, Liu X.   +8 more
europepmc   +1 more source

The Evaluation of the Clinical Effectiveness and Safety of Biologic Therapies in Psoriasis-Real-World Evidence up to 64 Weeks of Therapy. [PDF]

Med Sci (Basel)
Lemiesz P, Nowowiejska-Purpurowicz J, Kaminski TW, Flisiak I.   +3 more
europepmc   +1 more source

Interleukin-23 Inhibitors in Inflammatory Bowel Disease. [PDF]

BioDrugs
Puca P, Parello S, Colantuono S, Tursi A, Coppola G, Lopetuso LR, Scaldaferri F, Gasbarrini A, Papa A.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Guselkumab

Reactions Weekly
  +12 more sources

Guselkumab for the Treatment of Psoriasis

Expert Opinion on Biological Therapy, 2018
Psoriasis is a common, chronic, immune-mediated, inflammatory skin disease with systemic involvement and significant impact on patients' quality of life. Several biologic treatments have been developed in recent decades, such as tumor necrosis factor (TNF)-α inhibitors, a non-selective interleukin (IL)-23 inhibitor (ustekinumab, which also inhibits IL ...
Anna Balato, Annunziata Raimondo, Matteo Megna   +2 more
exaly   +8 more sources